I think it was ThinkEquity Q&A, when he said CFO did some calculations and said HIV should be well into double digits. That matches my valuations, but the unknowns are alone or license %, market penetration and annual price.....and these can all vary greatly, but my calculator always comes back to well into double digits with both combo and mono at conservative/reasonable valuations.

Cancer is the largest game changer.